Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAT2A | P31153 | 17/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26124606 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAT2APRMT5KDM4E | |
| SCHEMBL26125920 | 0.87 | MAPK8 (0.49) | MAPK8MAPK9MAT2APRMT5KDM4E | |
| SCHEMBL30608069 | 0.87 | MAPK8 (0.49) | MAPK8MAPK9MAT2APRMT5KDM4E | |
| SCHEMBL30608050 | 0.87 | MAPK8 (0.49) | MAPK8MAPK9MAT2APRMT5KDM4E | |
| SCHEMBL26128344 | 0.87 | MAPK8 (0.49) | MAPK8MAPK9MAT2APRMT5KDM4E | |
| SCHEMBL8178799 | 0.86 | KDM4E (0.46) | MAPK8MAPK9KDM4ENPSR1MEN1 | |
| SCHEMBL30358964 | 0.84 | MAT2A (0.48) | MAPK8MAPK9MAT2AKDM4ENPSR1 | |
| SCHEMBL28978826 | 0.84 | MAT2A (0.48) | MAPK8MAPK9MAT2AKDM4ENPSR1 | |
| SCHEMBL13384794 | 0.80 | KDM4E (0.47) | MAT2AKDM4ENPSR1MEN1LMNA | |
| SCHEMBL30358981 | 0.79 | MAPK8 (0.42) | MAPK8MAPK9MAT2APRMT5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116924983-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | MAPK8 2725/4885MAPK9 3983/4885MAT2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.